Free Trial
→ Your $29.97 book is free today (From Profits Run) (Ad)tc pixel Free RVX Stock Alerts

Resverlogix (RVX) Competitors

Resverlogix logo
C$0.10 -0.01 (-5.00%)
As of 03:24 PM Eastern
Compare

RVX vs. SCYB, COM, NVH, IGX, and PDP

Should you be buying Resverlogix stock or one of its competitors? The main competitors of Resverlogix include Scythian Biosciences (SCYB), 138267 (COM.TO) (COM), Novoheart (NVH), IntelGenx Technologies (IGX), and Pediapharm (PDP). These companies are all part of the "biotechnology" industry.

How does Resverlogix compare to Scythian Biosciences?

Scythian Biosciences (CVE:SCYB) and Resverlogix (TSE:RVX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and earnings.

0.0% of Resverlogix shares are owned by institutional investors. 42.7% of Resverlogix shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Resverlogix had 1 more articles in the media than Scythian Biosciences. MarketBeat recorded 1 mentions for Resverlogix and 0 mentions for Scythian Biosciences. Scythian Biosciences' average media sentiment score of 0.00 equaled Resverlogix'saverage media sentiment score.

Company Overall Sentiment
Scythian Biosciences Neutral
Resverlogix Neutral

Resverlogix's return on equity of 8.40% beat Scythian Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Scythian BiosciencesN/A N/A N/A
Resverlogix N/A 8.40%-34.90%

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Scythian BiosciencesN/AN/AN/AN/AN/A
ResverlogixN/AN/A-C$2.81M-C$0.03N/A

Summary

Resverlogix beats Scythian Biosciences on 4 of the 5 factors compared between the two stocks.

How does Resverlogix compare to 138267 (COM.TO)?

Resverlogix (TSE:RVX) and 138267 (COM.TO) (TSE:COM) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, earnings, dividends, risk, analyst recommendations and institutional ownership.

Resverlogix's return on equity of 8.40% beat 138267 (COM.TO)'s return on equity.

Company Net Margins Return on Equity Return on Assets
ResverlogixN/A 8.40% -34.90%
138267 (COM.TO) N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ResverlogixN/AN/A-C$2.81M-C$0.03N/A
138267 (COM.TO)N/AN/AN/AN/AN/A

In the previous week, Resverlogix had 1 more articles in the media than 138267 (COM.TO). MarketBeat recorded 1 mentions for Resverlogix and 0 mentions for 138267 (COM.TO). Resverlogix's average media sentiment score of 0.00 equaled 138267 (COM.TO)'saverage media sentiment score.

Company Overall Sentiment
Resverlogix Neutral
138267 (COM.TO) Neutral

0.0% of Resverlogix shares are owned by institutional investors. 42.7% of Resverlogix shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Resverlogix beats 138267 (COM.TO) on 4 of the 5 factors compared between the two stocks.

How does Resverlogix compare to Novoheart?

Resverlogix (TSE:RVX) and Novoheart (CVE:NVH) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, earnings, dividends, analyst recommendations, institutional ownership and valuation.

Resverlogix's return on equity of 8.40% beat Novoheart's return on equity.

Company Net Margins Return on Equity Return on Assets
ResverlogixN/A 8.40% -34.90%
Novoheart N/A N/A N/A

Resverlogix has higher earnings, but lower revenue than Novoheart. Novoheart is trading at a lower price-to-earnings ratio than Resverlogix, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ResverlogixN/AN/A-C$2.81M-C$0.03N/A
NovoheartC$423.50K236.08-C$7.17M-C$0.04N/A

In the previous week, Resverlogix had 1 more articles in the media than Novoheart. MarketBeat recorded 1 mentions for Resverlogix and 0 mentions for Novoheart. Resverlogix's average media sentiment score of 0.00 equaled Novoheart'saverage media sentiment score.

Company Overall Sentiment
Resverlogix Neutral
Novoheart Neutral

0.0% of Resverlogix shares are held by institutional investors. 42.7% of Resverlogix shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Resverlogix beats Novoheart on 7 of the 9 factors compared between the two stocks.

How does Resverlogix compare to IntelGenx Technologies?

IntelGenx Technologies (CVE:IGX) and Resverlogix (TSE:RVX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, media sentiment, valuation, earnings, institutional ownership, analyst recommendations and dividends.

0.0% of Resverlogix shares are held by institutional investors. 42.7% of Resverlogix shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Resverlogix has lower revenue, but higher earnings than IntelGenx Technologies. IntelGenx Technologies is trading at a lower price-to-earnings ratio than Resverlogix, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IntelGenx TechnologiesC$1.75M49.95-C$11.74M-C$0.08N/A
ResverlogixN/AN/A-C$2.81M-C$0.03N/A

Resverlogix's return on equity of 8.40% beat IntelGenx Technologies' return on equity.

Company Net Margins Return on Equity Return on Assets
IntelGenx TechnologiesN/A N/A N/A
Resverlogix N/A 8.40%-34.90%

In the previous week, Resverlogix had 1 more articles in the media than IntelGenx Technologies. MarketBeat recorded 1 mentions for Resverlogix and 0 mentions for IntelGenx Technologies. IntelGenx Technologies' average media sentiment score of 0.00 equaled Resverlogix'saverage media sentiment score.

Company Overall Sentiment
IntelGenx Technologies Neutral
Resverlogix Neutral

Summary

Resverlogix beats IntelGenx Technologies on 7 of the 9 factors compared between the two stocks.

How does Resverlogix compare to Pediapharm?

Pediapharm (CVE:PDP) and Resverlogix (TSE:RVX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, media sentiment, valuation, earnings, institutional ownership, analyst recommendations and dividends.

Resverlogix's return on equity of 8.40% beat Pediapharm's return on equity.

Company Net Margins Return on Equity Return on Assets
PediapharmN/A N/A N/A
Resverlogix N/A 8.40%-34.90%

0.0% of Resverlogix shares are held by institutional investors. 42.7% of Resverlogix shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Resverlogix had 1 more articles in the media than Pediapharm. MarketBeat recorded 1 mentions for Resverlogix and 0 mentions for Pediapharm. Pediapharm's average media sentiment score of 0.00 equaled Resverlogix'saverage media sentiment score.

Company Overall Sentiment
Pediapharm Neutral
Resverlogix Neutral

Resverlogix has lower revenue, but higher earnings than Pediapharm. Pediapharm is trading at a lower price-to-earnings ratio than Resverlogix, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PediapharmC$11.16M5.95-C$16.15M-C$0.07N/A
ResverlogixN/AN/A-C$2.81M-C$0.03N/A

Summary

Resverlogix beats Pediapharm on 7 of the 9 factors compared between the two stocks.

Get Resverlogix News Delivered to You Automatically

Sign up to receive the latest news and ratings for RVX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RVX vs. The Competition

Export
MetricResverlogixBiotechnology IndustryMedical SectorTSE Exchange
Market CapC$30.04MC$446.06MC$6.25BC$11.72B
Dividend Yield7.02%3.86%2.73%6.22%
P/E Ratio-3.174.1929.0423.83
Price / SalesN/A6,879.71476.6113.46
Price / Cash132.5013.1327.6282.69
Price / Book-0.3177.749.674.48
Net Income-C$2.81M-C$96.07MC$3.55BC$300.68M
7 Day PerformanceN/A0.71%1.70%0.12%
1 Month PerformanceN/A3.87%5.62%2.88%
1 Year PerformanceN/A48.54%34.41%57.78%

Resverlogix Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RVX
Resverlogix
N/AC$0.10
-5.0%		N/AN/AC$30.04MN/AN/A19
SCYB
Scythian Biosciences
N/AC$3.49
-5.9%		N/AN/AC$102.38MN/AN/AN/A
COM
138267 (COM.TO)
N/AN/AN/AN/AC$102.19MN/AN/AN/A
NVH
Novoheart
N/AC$0.53
+1.9%		N/AN/AC$99.98MC$423.50KN/AN/A
IGX
IntelGenx Technologies
N/AC$0.58
+1.8%		N/AN/AC$87.32MC$1.75MN/A2,050

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (TSE:RVX) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
The $1.75T "Backdoor" ticker (NOT Starlink)
When the SpaceX IPO launches, most investors will already be too late. The real opportunity isn't the IPO itse...
Behind the Markets | Sponsoredtc pixel
Sell 99% of Your Stocks, Do THIS Instead…
Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...
The Oxford Club | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Elon Unveils AI Passive Income Stream for Millions of Americans
During Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...
InvestorPlace | Sponsoredtc pixel